Review
Version 1
Preserved in Portico This version is not peer-reviewed
Gene Editing: The Regulatory Perspective
Version 1
: Received: 28 July 2023 / Approved: 28 July 2023 / Online: 31 July 2023 (04:55:07 CEST)
How to cite: Niazi, S.K. Gene Editing: The Regulatory Perspective. Preprints 2023, 2023072062. https://doi.org/10.20944/preprints202307.2062.v1 Niazi, S.K. Gene Editing: The Regulatory Perspective. Preprints 2023, 2023072062. https://doi.org/10.20944/preprints202307.2062.v1
Abstract
Gene or genome editing (GE) revises, removes, or replaces a mutated gene at the DNA level; it is a tool. Gene therapy (GT) offsets mutations by introducing a "normal" version of the gene into the body while the diseased gene remains in the genome; it is a medicine. So far, no GE product has been approved, as opposed to 22 GT products that cost up to millions of dollars per dose. The FDA has recently added a guideline specific to gene editing that should be understood to enable faster development of GE products; at the same time, the FDA also needs to bring more clarification and make several amendments to this guideline to make it more rational.
Keywords
gene editing; gene therapy; FDA; regulatory approval
Subject
Medicine and Pharmacology, Clinical Medicine
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment